The Pharma Data

OCTOBER 14, 2021

Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Preliminary results suggest that anti-CD20 and sphingosine 1-phosphate (S1P) therapies may reduce the antibody response to COVID-19 vaccination. Using data from the MS PATHS network in the U.S.,

Vaccine 52

Vaccine Therapies Immune Response Disease 52

The Pharma Data

JULY 6, 2021

Sanofi highlights scientific innovations in the field of rare blood disorders at I STH 2021. New research from first-in-class marketed and investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura will be presented. ePoster Abstract # OC48.2

Therapies 52

Therapies Pharmacokinetics RNA Treatment 52

The Pharma Data

JANUARY 11, 2021

Dalcetrapib is a potential anti-viral treatment that binds to the catalytic site of 3CLMpro of SARS-CoV-2 in vitro. Speaking to the Reuters Next conference, Dale Fisher, chairman of the World Health Organization’s (WHO) Outbreak Alert and Response Network, said that achievement of herd immunity in most countries is unlikely in 2021.

Vaccine 52

Vaccine Clinical Trials Immune Response Trials 52

The Pharma Data

APRIL 15, 2022

In December 2021, Pfizer and BioNTech announced the companies would test a third 3 µg dose given at least two months after the second dose in children under age 5 and a third dose of the 10 µg formulation in children 5 to under 12 years of age. The trial enrolled children with or without prior evidence of SARS-CoV-2 infection.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

AUGUST 27, 2020

Moderna has announced that its coronavirus vaccine candidate has shown promise in generating an immune response in elderly patients in an early-stage clinical trial. . The company has already tested the treatment on 10 adults between the ages of 56-70, and 10 over 71. Conor Kavanagh. Source link.

Vaccine 90

Vaccine Immune Response Clinical Trials Virus 90

The Pharma Data

FEBRUARY 22, 2021

New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. If results are positive, Phase 3 study to start in Q2 2021, with vaccine expected to be available in Q4 2021. In parallel, development work on new SARS-CoV-2 variants underway.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

MAY 12, 2021

New data to be featured at EHA 2021 Congress highlight Sanofi’s ongoing commitment to rare blood disorders. Additional data to be shared on rilzabrutinib, an investigational, peripheral Bruton’s tyrosine kinase (BTK) inhibitor with Tailored Covalency ® technology intended to treat immune thrombocytopenic purpura (ITP).

Disease 40

Disease FDA Treatment Therapies 40

The Pharma Data

JANUARY 25, 2021

25, 2021 — Giving melanoma patients a “personalized” vaccine can prompt an anti-tumor immune response that lasts for years, an early study finds. But it builds on earlier work showing it is possible to spur the immune system to respond to an individual’s unique tumor. 21, 2021, online.

Vaccine 52

Vaccine Immune Response Medical Schools Clinical Trials 52

The Pharma Data

APRIL 8, 2021

AstraZeneca will share updates from the Company’s innovative early oncology pipeline across multiple strategic platforms during the virtual American Association of Cancer Research (AACR) Annual Meeting, 10 to 15 April 2021. The introduction of AZD8853, a novel antibody targeting GDF15 for tumours refractory to immunotherapy treatment.

DNA 52

DNA Immune Response Therapies Treatment 52

The Pharma Data

MARCH 11, 2021

Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. Expected to enroll 415 participants; interim results expected in Q3 2021. The Companies expect interim results from this trial in the third quarter of 2021. About Translate Bio.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

JANUARY 3, 2021

Anecdotal feedback from Foralumab-treated patients was positive and suggests that the treatment was well-tolerated. This trial is the first to evaluate nasally administered Foralumab to improve the immune system’s fight against coronaviruses. NEW YORK and LONDON, Jan. NEW YORK and LONDON, Jan.

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

The Pharma Data

SEPTEMBER 8, 2021

While these results are disappointing, w e believe th e rilzabrutinib clinical program holds great potential to address the unmet treatment needs of people living with immune-mediated diseases , ” said Naimish Patel, Head of Global Development, Immunology and Inflammation. “ About the PEGASUS study.

Immune Response 52

Immune Response Trials Treatment Disease 52

The Pharma Data

JANUARY 12, 2021

It is being developed for the treatment of solid tumors. Dr. Ben-Moshe told BioSpace that BND-22 differs from traditional immunotherapy in that it can elicit a more total immune response. . “It It is a new immune checkpoint that is expressed on three different immune cells: Macrophages, [Natural Killer] NK cells, and T cells. [It]

Immune Response 52

Immune Response Clinical Trials Licensing Licensing 52

The Pharma Data

DECEMBER 30, 2020

The Phase I/II study results, together with recently generated preclinical data, indicate that ARCT-021 leads to a potent immune response to SARS-CoV-2, and demonstrates a differentiated biological profile whereby the immune response increases in the weeks following vaccination, the company said. billion by 2027.

Immune Response 52

Immune Response Vaccine Clinical Trials Treatment 52

The Pharma Data

JANUARY 3, 2021

I look forward to working with Scott and his team at NexImmune to help advance and expand the Company’s research and development pipeline with the ultimate goal of developing next-generation immunotherapies for patients suffering from immune-mediated conditions related to cancers and autoimmune/inflammatory diseases,” Dr. Zeldis commented. “It

Immune Response 40

Immune Response Clinical Trials Therapies Cell Biology 40

Drug Target Review

OCTOBER 26, 2023

1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications. His mentorship produced numerous publications.

Engineering 105

Engineering Virus Therapies Immune Response 105

The Pharma Data

DECEMBER 23, 2020

Based upon an interim analysis, an independent DMC recommended on December 21, 2020 the continuation of Inotrem’s Phase IIa clinical trial for which results are expected early Q2 2021. PARIS–( BUSINESS WIRE )– Inotrem S.A., Marc Derive. Inotrem is supported by leading European and North American investors.

Clinical Trials 52

Clinical Trials Trials Research Immune Response 52

The Pharma Data

NOVEMBER 9, 2020

Additionally, the vast majority of patients only receive a temporary benefit or no benefit from ICIs, as they either develop resistance to the treatment during the course of therapy or are non-responsive to the treatment altogether (only 15%-20% of patients respond, according to published data). Next Steps in Immunotherapy.

Immune Response 40

Immune Response Therapies Clinical Trials Treatment 40

Drug Target Review

JUNE 1, 2023

The research identifies the vulnerable sites on the spike protein that can be targeted by human antibodies, providing valuable information for the development of future vaccines and antibody treatments. Preclinical studies in mice suggest that some of these antibodies may also be effective in preventing severe cases of COVID-19. “To

Virus 97

Virus Vaccine Immune Response Research 97

The Pharma Data

MAY 15, 2023

The team at XinThera has developed research assets with the potential to target the DNA damage repair pathway in treating cancer and direct the body’s immune response in inflammatory diseases, both of which may improve outcomes for people living with these diseases,” said Flavius Martin, M.D., Qing Dong, Ph.D., and Gene Hung, M.D.,

Small Molecule 40

Small Molecule DNA Immune Response Science 40

The Pharma Data

JANUARY 6, 2021

7, 2021 /PRNewswire/ — ImaginAb Inc. , Quantitative imaging of CD8 T cells enables quicker identification of drug efficacy, therefore potentially reducing the length of clinical trials, reducing costs and helping new therapies to advance to market faster, which ultimately will improve treatment and care of cancer patients.

Licensing 52

Licensing Licensing Clinical Trials Pharmaceutical Companies 52

The Pharma Data

JUNE 24, 2021

Secondary objectives are to describe immune responses produced by each of the vaccines. Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer BioNTech COVID-19 Vaccine. The Pfizer?BioNTech

Vaccine 52

Vaccine Immune Response FDA Licensing 52

The Pharma Data

FEBRUARY 18, 2022

“For clinicians treating patients with this serious, chronic disease, results from the True North extension study provide an understanding of long-term therapeutic outcomes and help to identify an appropriate treatment approach for their patients with ulcerative colitis,” said Silvio Danese, M.D., About Ulcerative Colitis.

Clinical Trials 40

Clinical Trials Treatment Immune Response Disease 40

The Pharma Data

JANUARY 12, 2021

“The T-cell and NK-cell target discovery approach complements our portfolio aimed at turning cold tumors hot and redirecting the innate immune system to elicit a sustained and durable immune response against tumors. About KSQ Therapeutics.

Therapies 52

Therapies Immune Response Research Engineering 52

The Pharma Data

OCTOBER 26, 2020

FDA Approval: Last week the FDA approved Veklury (remdesivir) for the treatment of COVID-19 requiring hospitalization in adults and pediatric patients (12 years of age and older). Only a fraction of intravenous antibody treatments will make their way to the lungs of COVID-19 patients, which is where the infection is primarily located.

Vaccine 52

Vaccine FDA Approval FDA Clinical Trials 52

The Pharma Data

OCTOBER 21, 2020

T cell therapy expressing a chimeric antigen receptor (CAR) targeting CD20 for treatment of non-Hodgkin’s lymphoma (NHL). We believe that ADI-001 offers the opportunity for on demand treatment, selective tumor targeting, innate and adaptive anti-tumor immune response, and durable activity in patients. About ADI-001.

FDA 40

FDA Immune Response Engineering Clinical Trials 40

The Pharma Data

JANUARY 11, 2021

11, 2021 — Concerns about “long-haul” symptoms in COVID-19 survivors may be reignited by a new study: It finds that 3 out of 4 patients from Wuhan, China — where the pandemic originated — were still suffering at least one lingering health problem six months later. © 2021 HealthDay. Posted: January 2021.

Hospitals 52

Hospitals Virus Vaccine Immune Response 52

Agency IQ

APRIL 26, 2024

Background: PFAS and CERCLA In late 2021, the EPA published the PFAS Strategic Roadmap for 2021-2024 , which noted the intention to include certain PFAS under CERCLA. CERCLA liability is strict, retroactive, and joint and several. This means that a polluter is liable whether or not they knew they were polluting.

Government 40

Government Regulations Immune Response Treatment 40

The Pharma Data

JULY 23, 2021

These doses are expected to be delivered from October 2021 through April 2022. In a separate announcement on June 10, 2021, Pfizer and BioNTech shared plans to provide the U.S. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. This brings the total number of doses to be supplied by the companies to the U.S.

Vaccine 52

Vaccine Government Immune Response FDA 52

The Pharma Data

DECEMBER 27, 2020

(NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided a year-end review and an outline of its plans for 2021.

Therapies 52

Therapies Clinical Trials Production Treatment 52

NIH Director's Blog: Drug Development

MARCH 18, 2021

Now, Veesler and his lab are turning to another mammal in their search for new leads for the next generation of antiviral treatments, including ones aimed at the coronavirus that causes COVID-19, SARS-CoV-2. And, how can those structural differences serve as blueprints for promising new treatments to combat many potentially deadly viruses?

Virus 52

Virus Immune Response Clinical Trials Treatment 52

The Pharma Data

JANUARY 17, 2021

18, 2021 09:00 UTC. By exploring multiple therapies across oncology and cardiovascular, genetic, neurological and autoimmune diseases, we are well positioned to bring life-changing treatments to multiple patient populations with critical unmet needs.”.

Therapies 40

Therapies Clinical Trials Immune Response Disease 40

The Pharma Data

MARCH 25, 2022

Evusheld is the only long-acting antibody combination with positive Phase III data in the prevention and treatment of COVID-19.3,9 AstraZeneca is progressing with filings around the globe for potential emergency use authorisation or marketing approval of Evusheld in both COVID-19 prophylaxis and treatment.

Vaccine 52

Vaccine Virus Immune Response Trials 52

Agency IQ

DECEMBER 1, 2023

That guidance, first issued in May 2020 , was released at a time when there were no FDA-approved drugs to treat Covid-19, and the standard-of-care for treatment relied on clinical management of symptoms and supportive care (e.g., About one year after its initial publication, FDA updated the guidance in February 2021.

FDA 40

FDA Clinical Trials Vaccine Trials 40

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

Yet the quest to save more lives from COVID-19 isn’t even close to being finished, and researchers continue to work intensively to develop new and better treatments. They are called immune modulators because they help to minimize the effects of an overactive immune response in some COVID-19 patients.

Clinical Trials 52

Clinical Trials Trials Hospitals Vaccine 52

The Pharma Data

DECEMBER 29, 2020

The analysis was prospectively designed to focus on patients who had not yet mounted their own immune response to SARS-CoV-2 (i.e., The company expects to complete the manufacture of these doses on schedule in January 2021 and is in discussions with the U.S. futility analysis). The results passed the futility analysis (p<0.3

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

APRIL 28, 2021

PARIS – April 23, 2021 – New analyses from Dupixent ® (dupilumab) trials evaluated infection incidence reduction and reinforced the need for no laboratory monitoring in patients six years and older with moderate-to-severe atopic dermatitis. These data will be presented as a late-breaking abstract oral presentation at AAD VMX 2021.

Laboratories 40

Laboratories Disease Trials Clinical Trials 40